DeepMed Research

HAEMONETICS CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

An Observational Trial to Assess the Performance of the TEG® 6s Diagnostic System With the Citrated K, KH, RTH, FFH Cartridge

Completed

Conditions: Surgery

Interventions: Diagnostic Test: TEG 6s Citrated K, KH, RTH, FFH Cartridge
Diagnostic Test: Clauss Fibrinogen

First Posted Date: 2024-04-08

Last Posted Date: 2024-04-08

Lead Sponsor: Haemonetics Corporation

Target Recruit Count: 338

Registration Number: NCT06352125

Locations: 🇺🇸
Ochsner Clinic, New Orleans, Louisiana, United States
🇺🇸
Lifebridge Health (Sinai Hospital), Baltimore, Maryland, United States
🇺🇸
University of Colorado, Aurora, Colorado, United States

and more 4 locations

Normal Reference Range Study With the TEG6s Heparin Neutralization Cartridge in Healthy Volunteers

Completed

Conditions: Healthy

Interventions: Diagnostic Test: TEG 6s Citrated K, KH, RTH, and FFH Cartridge
Diagnostic Test: Clauss Fibrinogen

First Posted Date: 2024-02-15

Last Posted Date: 2024-02-15

Lead Sponsor: Haemonetics Corporation

Target Recruit Count: 181

Registration Number: NCT06261580

Locations: 🇺🇸
Louisiana Coagulation / Machaon Division, New Orleans, Louisiana, United States
🇺🇸
Machaon Diagnostics, Oakland, California, United States
🇺🇸
Cardiovascular Research Institute - Loyola University Chicago Health Sciences, Maywood, Illinois, United States

IMPACT (Improving Plasma Collection) Clinical Trial

Not Applicable

Completed

Conditions: Apheresis Related Hypotension

Interventions: Device: Updated Plasma Collection Feature
Device: Current Plasma Collection Approach

First Posted Date: 2020-03-25

Last Posted Date: 2021-04-09

Lead Sponsor: Haemonetics Corporation

Target Recruit Count: 3443

Registration Number: NCT04320823

Locations: 🇺🇸
Octapharma Plasma, Spokane, Washington, United States

Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System

Completed

Conditions: DOAC Eligible Subjects

Interventions: Device: TEG6s DOAC Cartridge

First Posted Date: 2016-06-14

Last Posted Date: 2020-02-11

Lead Sponsor: Haemonetics Corporation

Target Recruit Count: 385

Registration Number: NCT02798328

Locations: 🇺🇸
Spartanburg Regional Healthcare System, Spartanburg, South Carolina, United States
🇺🇸
Essentia Institute of Rural Health, Duluth, Minnesota, United States
🇺🇸
Inova Health Care Services, Falls Church, Virginia, United States

and more 1 locations

Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder

Not Applicable

Completed

Conditions: Transmission, Blood, Recipient/Donor

Interventions: Device: POLFA (Needle Assembly)
Device: Kawasumi (Needle Assembly)

First Posted Date: 2015-06-19

Last Posted Date: 2022-04-29

Lead Sponsor: Haemonetics Corporation

Target Recruit Count: 62

Registration Number: NCT02476851

Locations: 🇺🇸
Hoxworth Blood Center, Cincinnati, Ohio, United States
🇺🇸
American Red Cross Mid-Atlantic Region Blood Services, Norfolk, Virginia, United States
🇺🇸
Haemonetics, Braintree, Massachusetts, United States

Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution

Phase 1

Completed

Conditions: Blood Donors

Interventions: Drug: SOLX (Investigational)
Drug: AS-3 (Control)

First Posted Date: 2014-05-23

Last Posted Date: 2022-04-25

Lead Sponsor: Haemonetics Corporation

Target Recruit Count: 170

Registration Number: NCT02145507

Locations: 🇺🇸
American Red Cross Mid-Atlantic Region Blood Services, Norfolk, Virginia, United States
🇺🇸
Hoxworth Blood Center, Cincinnati, Ohio, United States

Procedure For The Reference Range Study For Absolute MA

Completed

Conditions: Transmission, Blood, Recipient/Donor

First Posted Date: 2014-04-10

Last Posted Date: 2015-04-03

Lead Sponsor: Haemonetics Corporation

Target Recruit Count: 161

Registration Number: NCT02110576

Locations: 🇺🇸
Denver Health Medical Center, Denver, Colorado, United States

Clinical Investigational Protocol for 2 RBC Single Unit Recovery on MCS®+ 8150 Using LN832 Disposable Sets (US)

Completed

Conditions: Red Blood Cell Donation

First Posted Date: 2013-01-09

Last Posted Date: 2013-10-11

Lead Sponsor: Haemonetics Corporation

Target Recruit Count: 60

Registration Number: NCT01764061

Locations: 🇺🇸
Blood Center of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
American Red Cross, Norfolk, Virginia, United States

Clinical Evaluation of the OrthoPAT Advance System

Completed

Conditions: Transmission, Blood, Recipient/Donor

Interventions: Device: OrthoPat Advance

First Posted Date: 2012-12-28

Last Posted Date: 2013-11-20

Lead Sponsor: Haemonetics Corporation

Target Recruit Count: 84

Registration Number: NCT01756976

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

RapidTEG MA Validation

Terminated

Conditions: Coagulation
Platelet Function

First Posted Date: 2011-09-02

Last Posted Date: 2013-09-16

Lead Sponsor: Haemonetics Corporation

Target Recruit Count: 17

Registration Number: NCT01428102

Locations: 🇺🇸
Univserity of Tennessee Health Sciences Center, Knoxville, Tennessee, United States
🇺🇸
Sinai Center for Thrombosis Research, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy